SCHEMBL761830

SCHEMBL761830

CN1CCC=CC1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8305417 0.86
SCHEMBL13507323 0.78 GSK3A (0.36)
SCHEMBL577436 0.76
SCHEMBL1062964 0.74
SCHEMBL11612617 0.72
SCHEMBL12574036 0.72
SCHEMBL4734305 0.70
SCHEMBL18116986 0.70
SCHEMBL9004338 0.70 POLB (0.32)
SCHEMBL11932068 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12240862-B2 Inhibitors of peptidylarginine deiminases GILEAD SCIENCES, INC. (US) 2025-03-04 US disclosed
CN-119031913-A Purine and methods of use thereof 奇尼塔公司 2024-11-26 CN disclosed
WO-2024092011-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2024-05-02 WO disclosed
CN-111212832-B 1-Benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as HIV protease inhibitors 吉利德科学公司 2023-09-15 CN disclosed
EP-3150592-B1 ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF SHANGHAI EMERALD WELLCARES PHARMACEUTICAL CO LTD (CN) 2023-08-30 EP disclosed
US-20230242548-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-08-03 US disclosed
WO-2023109909-A1 AROMATIC HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND USES THEREOF 上海翊石医药科技有限公司 2023-06-22 WO disclosed
WO-2023055020-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING VASCULAR DISEASES, COMPRISING PIPERLONGUMINE-BASED COMPOUND AS ACTIVE INGREDIENT 주성수 2023-04-06 WO disclosed
EP-3943087-A1 HETEROARYL COMPOUNDS AND USES THEREOF Celgene CAR LLC (BM) 2022-01-26 EP disclosed
EP-3224255-B1 N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2022-01-05 EP disclosed
US-7199149-B2 Monocyclic and bicyclic lactams as factor Xa inhibitors BRISTOL MYERS SQUIBB COMPANY (US) 2007-04-03 US disclosed
US-7169795-B2 Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors BRISTOL MYERS SQUIBB COMPANY (US) 2007-01-30 US disclosed
EP-1259514-B9 3-(PYROLYLLACTONE)-2-INDOLINONE COMPOUNDS AS KINASE INHIBITORS SUGEN INC (US) 2005-11-09 EP disclosed
EP-1259514-B1 3-(PYROLYLLACTONE)-2-INDOLINONE COMPOUNDS AS KINASE INHIBITORS SUGEN INC (US) 2005-06-08 EP disclosed
WO-2004082687-A1 LACTAM-CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-09-30 WO disclosed
EP-1259514-A2 3-(PYROLYLLACTONE)-2-INDOLINONE COMPOUNDS AS KINASE INHIBITORS Sugen, Inc. (US) 2002-11-27 EP disclosed
US-6465507-B2 ANTITUMOR AGENTS SUGEN, INC. 2002-10-15 US disclosed
US-20020042427-A1 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors SUGEN, INC. 2002-04-11 US disclosed
WO-2001064681-A2 3-(PYROLYLLACTONE)-2-INDOLINONE COMPOUNDS AS KINASE INHIBITORS SUGEN, INC. (US) 2001-09-07 WO disclosed
US-4105769-A Inhibition of indoleamine-N-methyl transferase by 2-iminopyridines MERCK & CO., INC. (US) 1978-08-08 US disclosed